Company Announcements

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

TETRIS PHARMA LAUNCHES OGLUO® IN DENMARK AND NORWAY

A new treatment option for severe hypoglycaemia for children and adults living with diabetes

Launches build on continued roll out in Austria, Germany and the UK

Cambridge, UK, 15 May 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that subsidiary company, Tetris Pharma Ltd, has today launched Ogluo® (glucagon prefilled autoinjector pen) in Denmark and Norway as a treatment for severe hypoglycaemia in adults, adolescents, and children aged two years and over living with diabetes mellitus.

See full Tetris Pharma announcement below:

15 May 2023 - Tetris Pharma Ltd ("Tetris Pharma" or "the Company"), a subsidiary of biopharmaceutical company, Arecor Therapeutics plc (AIM: AREC), today announces the launch of Ogluo® (glucagon prefilled autoinjector pen) in Denmark and Norway as a treatment for severe hypoglycaemia in adults, adolescents, and children aged two years and over living with diabetes mellitus.

Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon in an auto-injector for patients within the licenced indication living with diabetes suffering from severe hypoglycaemia¹. Hypoglycaemia is a common and serious complication of diabetes, particularly affecting people with diabetes on insulin treatment. It is characterised by abnormally low blood sugar levels, which can lead to cognitive impairment and in some severe cases, seizures, loss of consciousness, coma and even death. It can have a profound effect on the everyday lives of people with diabetes and their caregivers².

Ogluo® pricing has today been published in both Denmark and Norway allowing patients to access this rescue medication, full prescribing information can be found here. Ogluo® is also available in Austria, Germany and the UK. Tetris Pharma is working to commercialise Ogluo® in core European markets as part of a pan-European commercialisation programme.

Dr Shafiq Choudhary, European Managing Director of Tetris Pharma said: "With over half a million people estimated to be living with diabetes in Denmark and Norway alone³, the launch of Ogluo® gives patients living with diabetes an alternative ready to use, ambient stored glucagon that can be kept by the patients' side, giving their families and those around them the confidence to manage severe hypoglycaemic events. The launch extends our commercial footprint and pan-European presence."

1.      Ogluo SmPC

2.      Amiel, S.A. The consequences of hypoglycaemia. Diabetologia 64, 963-970 (2021). https://doi.org/10.1007/s00125-020-05366-3

3.      (IDF Atlas 10^th Edition 2021 Diabetes report https://diabetesatlas.org/data/en/country/148/no.html / https://www.diabetesatlas.org/data/en/country/56/dk.html ) Access Date:9/5/23

Enquiries:

Tetris Pharma

Dr Shafiq Choudhary      +44 (0)1628 337579

Notes to Editors

Tetris Pharma, a subsidiary of Arecor Therapeutics plc, is a commercial-stage specialty pharmaceutical company with expertise in registering, marketing, sales and the distribution of speciality hospital products across the UK and Europe. Our experienced team has a proven history of building and growing sales. Having secured distribution rights for already licensed products across Europe, we have a portfolio of niche injectable products including Ogluo^®, a ready-to-use glucagon for emergency use to treat hypoglycaemia. We collaborate with partners to provide patients with effective treatments and quality healthcare by ensuring we deliver accountability, partnership and performance.

For further information, please visit tetrispharma.com

-ENDS-

For more information, please contact:

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. 

For further details please see our website, www.arecor.com